Objective: Intrahepatic cholangiocarcinoma is the second most frequently encountered primary tumor of the liver after hepatocellular carcinoma. In patients who do not have surgical or other local treatment options, systemic chemotherapy is the standard treatment. However, prognostic factors are not clear for patients with advanced disease who do not have the ability to undergo a surgical operation. In many tumors, there are studies demonstrating the pretreatment effect of positron emission tomography with fluorodeoxyglucose (FDG-PET) metabolic parameters on the prognosis. However, there are a small number of studies that research the effect of FDG-PET metabolic parameters on the prognosis in advanced intrahepatic cholangiocarcinoma. We aimed to investigate the relationship between FDGPET metabolic parameters and survival in advanced intrahepatic cholangiocarcinoma.
Methods: The medical records of 50 advanced intrahepatic cholangiocarcinoma patients from Istanbul Bilim University Medical Oncology Clinic between 2012 and 2018 were reviewed retrospectively. The relationship between patient survival, demographic characteristics and FDG-PET metabolic parameters (SUVmax, metabolic tumor volume, and total lesion glycolysis) was analyzed.
Results: Each unit of increase in metabolic tumor volume increases the risk of death by 1.0057 times, and each unit of increase in total lesion glycolysis increases the risk of death by 1.0034 times. The Cox regression model was found to be significant for metabolic tumor volume and total lesion glycolysis values but not for SUVmax values.
Conclusion: FDG-PET metabolic parameters, such as metabolic tumor volume and total lesion glycolysis, contribute to the prognosis, and routine measurement of these parameters will be beneficial.
Dilip Pawar, Rusy Bhalla, Duleep Bhonsale, Seeemantini Bhalla
Background: Verrucous carcinoma or Ackerman’s tumor comprise 2% to 5% of oral cancer malignancies. It has a higher prevalence
in patients with use of Tobacco and related products. It is also associated with HPV infection. It is more common in middle aged and elderly
individuals. verrucous carcinoma is a locally proliferative disease and does not metastasize. It will not invade the underlying bone and
muscles and as such it is localized to mucosa. The verrucous carcinoma has the propensity to turn carcinomatous if not treated for a long
time. Histopathologically it is characterized by dysplasia without invasion of underlying dermis. Verrucous carcinoma is conventionally
treated by a mutilating surgery or radiation. Both these options have side effects which are not acceptable to patients. Laser gives an
easier way to handle this condition without any of side effects of above procedures. This was a retrospective analysis of verrucous
carcinoma cases where treatment was given in the form of laser ablation of the growth. Laser was used to ablate the visualized tumor and
followed up with minor ablative sessions. Sites included were buccal mucosa 50%, RMT area with buccal mucosa 15%, Tongue 25%, 10%
had on genitalia. No radiation or any other chemotherapy was administered.
Eric Heller*, Kranti A. Mapuskar, Kelli Hawkes, Heba Ismael, Kristin Plichta, Kellie L. Bodeker, Sarah L. Mott, Barry London, Douglas R. Spitz, Bryan G. Allen, Elizabeth A. Chrischilles and Isabella M. Grumbach
DOI: 10.37421/2476-2261.2025.11.331
Radiation-associated cardiac disease frequently affects cancer patients when radiation fields overlap the heart, but relationships between cardiac substructure dose and specific cardiac events remain poorly understood. This study examined associations between radiation dose to cardiac substructures and adverse cardiac events in thoracic malignancy patients. We retrospectively analyzed 94 patients with lung, esophageal and breast cancers who received radiation therapy. Radiation-induced adverse cardiac events included pericardial disease, atrial fibrillation/flutter, heart failure and valve disease. We evaluated associations between cardiac substructure radiation doses and adverse event types. Results showed that increasing radiation doses to the pericardium, left atrium and whole heart were associated with higher odds of pericardial disease. Median onset times varied: 7 months for pericardial disease, 10 months for atrial fibrillation/flutter and 16 months for heart failure. Clear associations emerged between specific cardiac substructure radiation doses and corresponding adverse event types. Sex-specific differences in cardiac substructure radiation dose were also identified. These findings demonstrate important relationships between cardiac substructure radiation exposure and specific adverse events in patients receiving thoracic radiation therapy. The results underscore the critical importance of considering both cardiac substructure dose distributions and patient sex when developing strategies to mitigate treatment-related cardiac risks in cancer patients.
Kunpeng Jia, Lexi Huang, Yuanhao Xu and Lingjiao Xiang*
Journal of Oncology Translational Research received 93 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 